Labeling of Drug and Biologic Products for Pediatric Use
Drugs and biological therapeutics are commonly prescribed to pediatric patients in the absence of adequate dosage and administration information in the product label. This paper describes issues surrounding labeling of drugs and biologies for pediatric use. It includes a discussion of why drugs and biologies should be labeled with pediatric use information, an update on the status of regulatory guidance for pediatric labeling, and a summary of recent steps taken by the Food and Drug Administration (FDA) to increase the number of therapeutic products that contain appropriate labeling for pediatric use.
Key WordsDrugs Biologies Labeling Pediatrics Regulations
Unable to display preview. Download preview PDF.
- 1.Committee on Drugs, American Academy of Pediatrics. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics. 1995;95(2):286–294.Google Scholar
- 2.Food and Drug Administration. Specific requirements on content and format of labeling for human prescription drugs; revision of “pediatric use” subsection in the labeling; final rule. Federal Register. 1994;59(December 13):64240–64250.Google Scholar
- 4.Food and Drug Administration. Pediatric Patients; Regulations Requiring Manufacturers To Assess the Safety and Effectiveness of New Drugs and Biological Products. Federal Register. 1997;62(158) (August 15):43900–43916.Google Scholar
- 9.Food and Drug Administration. Labeling and pre-scription drug advertising: content and format for labeling for human prescription drugs. Federal Register. 1979;44(June 26):37434–37467.Google Scholar